Risk factors for biliary stent infections in malignant biliary obstruction secondary to unresectable malignancies

被引:1
|
作者
Petit, Sebastien [1 ]
Puyade, Mathieu [2 ]
Pichon, Maxime [1 ,3 ,4 ]
Wangermez, Marc [5 ]
Velasco, Stephane [6 ]
Roblot, France [1 ,2 ,4 ]
Isambert, Nicolas [1 ,7 ]
Evrard, Camille [7 ]
Rammaert, Blandine [1 ,2 ,4 ]
机构
[1] Univ Poitiers, Fac Med & Pharm, Poitiers, France
[2] CHU Poitiers, Serv Med Interne & Malad Infect & Trop, 2 Rue Mil,CS 90577, F-86021 Poitiers, France
[3] CHU Poitiers, Dept Agents Infect, Lab Bacteriol & Hyg Hosp, Poitiers, France
[4] INSERM, U1070, Poitiers, France
[5] CHU Poitiers, Serv Hepato Gastroenterol, Poitiers, France
[6] CHU Poitiers, Serv Radiol Intervent, Poitiers, France
[7] CHU Poitiers, Pole Reg Cancerol, Serv Oncol Med, Poitiers, France
关键词
Cholangitis; Malignant biliary obstruction; Self-expandable metallic stents; Cancer; Biliary drainage; Transpapillary stenting; MAIN DUODENAL PAPILLA; PLASTIC STENTS; METALLIC STENTS; BLOOD CULTURE; BILE CULTURE; COMPLICATIONS; PLACEMENT; CANCER; GUIDELINES; MANAGEMENT;
D O I
10.1007/s00520-022-07106-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Palliative biliary drainage in patients with unresectable malignant biliary obstruction (MBO) frequently leads to biliary stent infection (BI), which could impact medical care. The aim of this study was to assess the risk factors for BI occurrence in patients after stenting procedure and the impact of BI on patient survival. Methods All consecutive patients hospitalized from 2014 to 2018 for MBO and biliary stenting were retrospectively included. Demographic, clinical, and microbiological characteristics of each BI episode during a 1-year follow-up were described. Documented BI was defined as the association of BI episode and confirmed blood stream infection (BSI). Univariate and multivariate analyses were performed to evaluate risk factors for the first BI occurrence. Results Among 180 patients, 56% were men (mean age of 69 +/- 12), and 54% have pancreatic cancer, 16% biliary cancer, 2% hepatic cancer, and 28% lymph node or metastatic compression; metallic stent was placed in 92%. A total of 113 BI episodes occurred in 74 patients, 55% of the first episodes occurring within 3 months after stenting. BI was documented in 56% of the episodes. Enterobacteriaceae were the most frequent pathogens found, while no yeasts were documented. Mortality rate in patients with BI was 64%. Multivariate analysis showed a significant difference in BI occurrence for two criteria: WHO score 3-4 (OR=8.79 [1.79-42.89]; p=0.007) and transpapillary stenting location (OR=3.72 [1.33-10.44]; p=0.013). Conclusion Since transpapillary stenting is a risk factor for BI, preserving the papilla as much as possible is a priority so as to avoid BI.
引用
收藏
页码:6937 / 6946
页数:10
相关论文
共 50 条
  • [41] Outcomes and risk factors for cancer patients undergoing endoscopic intervention of malignant biliary obstruction
    Haag, Georg-Martin
    Herrmann, Thomas
    Jaeger, Dirk
    Stremmel, Wolfgang
    Schemmer, Peter
    Sauer, Peter
    Gotthardt, Daniel Nils
    BMC GASTROENTEROLOGY, 2015, 15
  • [42] Feasibility and safety of percutaneous transhepatic endobiliary radiofrequency ablation as an adjunct to biliary stenting in malignant biliary obstruction
    Acu, B.
    Ozturk, E. Kurtulus
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2018, 99 (04) : 237 - 245
  • [43] Multifactorial analysis of biliary infection after percutaneous transhepatic biliary drainage treatment of malignant biliary obstruction
    Yu, Haipeng
    Sun Yuanyuan
    Guo, Zhi
    Xing, Wenge
    Si, Tongguo
    Guo, Xiuying
    Liu, Fang
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (07) : 1503 - 1508
  • [44] Endoscopic ultrasound-guided transduodenal placement of a fully covered metal stent for palliative biliary drainage in patients with malignant biliary obstruction
    Siddiqui, Ali A.
    Sreenarasimhaiah, Jayaprakash
    Lara, Luis F.
    Harford, William
    Lee, Calvin
    Eloubeidi, Mohamad A.
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2011, 25 (02): : 549 - 555
  • [45] Malignant biliary obstruction: Management with percutaneous metallic stent placement
    Brountzos, EN
    Petropoulos, E
    Kelekis, NL
    Magoulas, D
    Alexopoulou, E
    Kagianni, E
    Kelekis, DA
    HEPATO-GASTROENTEROLOGY, 1999, 46 (29) : 2764 - 2771
  • [46] Percutaneous intraductal radiofrequency ablation combined with biliary stent placement for treatment of malignant biliary obstruction
    Yu, Tianzhu
    Zhang, Wei
    Li, Changyu
    Wang, Chenggang
    Gong, Gaoquan
    Wang, Liangwen
    Li, Guoping
    Chen, Yi
    Wang, Xiaolin
    ABDOMINAL RADIOLOGY, 2020, 45 (11) : 3690 - 3697
  • [47] Which is better for unresectable malignant hilar biliary obstruction: Side-by-side versus stent-in-stent?
    Naitoh, Itaru
    Inoue, Tadahisa
    Hayashi, Kazuki
    INTERNATIONAL JOURNAL OF GASTROINTESTINAL INTERVENTION, 2018, 7 (02): : 78 - 84
  • [48] Recent advances regarding endoscopic biliary drainage for unresectable malignant hilar biliary obstruction
    Kato, Hironari
    Matsumoto, Kazuyuki
    Okada, Hiroyuki
    DEN OPEN, 2022, 2 (01):
  • [49] Nitinol biliary stent versus surgery for palliation of distal malignant biliary obstruction
    Rodrigo Castaño
    Tercio L. Lopes
    Oscar Alvarez
    Victor Calvo
    Leticia P. Luz
    Everson L. A. Artifon
    Surgical Endoscopy, 2010, 24 : 2092 - 2098
  • [50] Secondary uncovered versus fully-covered metal stents for the management of occluded stent in unresectable distal malignant biliary obstruction
    Tejedor-Tejada, Javier
    Alvarez-Alvarez, Aranzazu
    Olmos, Jose Manuel
    Gonzalez-Bernal, Ana Cristina
    Jimenez-Jurado, Andrea
    Robles-Gaitero, Samuel
    Perez-Pariente, Jose M.
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2024, 47 (09):